Heart failure study to uncover hidden links to kidney and liver disease

NCT ID NCT07380828

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will follow 3000 adults with chronic heart failure to see how often they also have kidney disease, diabetes, fatty liver, or clogged arteries. Researchers want to understand how these conditions interact and affect patient outcomes over two years. No new treatments are being tested; the goal is to gather knowledge for better future care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could help doctors better predict and manage heart failure by understanding how it connects with other conditions like kidney disease and diabetes.

What could go wrong

This is an observational study, not a treatment trial. It will not directly test any new drug or therapy, so it may not lead to immediate changes in care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atherosclerosis cardiovascular-kidney-metabolic syndrome congestive heart failure heart failure Obesity type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••